A recently listed small-cap pharmaceutical company’s shares jumped up to 17% to an intraday high of Rs 584 after reporting robust Q3 numbers. The company saw an impressive 130% jump in its net profits during the quarter while its revenues are up by 31% YoY.
Share Price Movement
The shares of Senores Pharmaceuticals Ltd, closed at Rs 549 per share, which was around 10% above its previous close of Rs 498.50 apiece and with a market cap of Rs 2,512.91 Crores. The shares generated a 6.5% return over the past 5 days. The 52-week High of the shares was Rs 609 per share, with a 52-week Low of Rs 440 per share.
Q3FY25 Results
Senores Pharmaceuticals Ltd reported an increase of 131% in Net Profits Year-on-Year, from Rs 7.11 Crores in Q3FY24 to Rs 16.43 Crores in Q3FY25. Similarly, their revenue reported an increase of 31%, from Rs 78.70 Crores to Rs 103.02 Crores over the same period.
Their EBITDA saw a significant growth of around 92%, from Rs 15.2 Crores to Rs 29.1 Crores over the same period. The company’s profit margin increased from 9% in Q3FY24 to 16.1% in Q3FY25.
Revenue Breakup
In Q3FY24, the company generated the majority of its revenue from developed markets, contributing 87% of total revenue. Revenue from emerging markets accounted for 8.5%, while other markets contributed 4.5%. However, in Q3FY25, the revenue mix shifted, with developed markets contributing 68.1%, emerging markets rising to 25.3%, and other markets accounting for 6.6%.
Management Commentary
In Q3 FY25, the management highlighted the launch of one new product and the receipt of ANDA approval for five products in the developed markets business, bringing the total number of ANDA approvals to 24. Additionally, their registered product portfolio in the Emerging Markets business grew to 267 products.
Also read….
Operational Highlights
The company currently holds a diverse portfolio in both developed and emerging markets. In the developed markets, it has 22 owned commercial products, 24 approved ANDAs, and 51 pipeline products, including 28 in the CGT (Cell and Gene Therapy) opportunity category.
Additionally, it has 21 commercial products in CDMO/CMO (Contract Development and Manufacturing Organization/Contract Manufacturing Organization) and 69 pipeline products in this area. In emerging markets, the company boasts 237 approved products, with 537 products under registration, and maintains a presence in over 40 countries.
IPO Details
The price band for the IPO was set between ₹372 and ₹391 per share. The shares were listed on BSE and NSE on December 30, 2024, with a 53% premium at Rs 600 on NSE. The IPO raised ₹582.11 crores through a book-built process, comprising a fresh issue of 1.28 crore shares and an offer for sale of 0.21 crore shares.
About Senores Pharmaceuticals Ltd
Senores Pharmaceuticals Limited is a global, research-driven pharmaceutical company focused on developing and manufacturing a broad range of pharmaceutical products. The company primarily serves developed markets like the US, Canada, and other emerging markets across various therapeutic areas and dosage forms. The company has manufactured over 270 Commercial products serving over 300 customers across 49 countries.
Written By Adhvaitha Nayani
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
